Roche Assures Investors: “Right Moment Is Now” To Acquire Genentech
This article was originally published in The Pink Sheet Daily
Roche would consider another Genentech-like deal, but the biotech itself has grown too large and the time is right to bring it in-house, Humer says.
You may also be interested in...
Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.
Roche offers to buy out Genentech’s minority stakeholders for $89 per share, or $43.7 billion, to create the seventh largest U.S. pharma company.
AstraZeneca’s North American CEO Zook will assume responsibilities until a successor is hired.